Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July
Executive Summary
FDA will bring AstraZeneca's oncologic Iressa back before the Oncologic Drugs Advisory Committee in June or July, Division of Oncologic Drug Products Director Richard Pazdur indicated
You may also be interested in...
Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review
Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA follow the recommendation of its Oncologic Drugs Advisory Committee and reject the current application
Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review
Abbott is counting on its back-up Phase III study to support Xinlay approval should FDA follow the recommendation of its Oncologic Drugs Advisory Committee and reject the current application
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials